UCB S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
792
541
1,319
807
1,194
1,290
Total Accounts Receivable
919
675
804
820
738
821
Inventories
627
547
566
578
597
647
Other Current Assets
86
738
149
126
148
192
Total Current Assets
2,424
2,501
2,838
2,331
2,677
2,950
Net Property, Plant & Equipment
722
686
651
678
673
805
Total Investments and Advances
86
155
198
174
174
127
Long-Term Note Receivable
24
23
207
23
23
23
Intangible Assets
6,006
6,101
6,219
6,053
5,655
5,840
Total Assets
9,760
10,148
10,956
10,212
9,917
10,514
ST Debt & Current Portion LT Debt
723
372
623
27
39
Accounts Payable
297
312
342
274
281
Income Tax Payable
114
142
553
328
96
Other Current Liabilities
1,211
1,510
1,543
1,789
1,533
Total Current Liabilities
2,345
2,336
3,061
2,418
1,949
Long-Term Debt
2,322
2,042
1,880
1,574
1,534
Provision for Risks & Charges
624
738
493
584
562
Deferred Taxes
386
620
795
943
662
Other Liabilities
329
423
223
149
83
Total Liabilities
5,732
5,601
5,705
4,735
4,181
Common Equity (Total)
4,159
4,707
5,377
5,584
5,813
Total Shareholders' Equity
4,159
4,707
5,377
5,584
5,813
Total Equity
4,028
4,547
5,251
5,477
5,736
Liabilities & Shareholders' Equity
9,760
10,148
10,956
10,212
9,917
Accumulated Minority Interest
131
160
126
107
77

About UCB

View Profile
Address
Allée de la Recherche, 60
Brussels BU 1070
Belgium
Employees -
Website http://www.ucb.com
Updated 07/08/2019
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.